Literature DB >> 16677867

Mitomycin C in the management of pediatric caustic esophageal strictures: a case report.

Oluyinka O Olutoye1, Robert J Shulman, Ronald T Cotton.   

Abstract

Although the incidence of caustic ingestion is declining, the management of caustic esophageal strictures remains a challenge. Mitomycin C (MMC) inhibits fibroblast proliferation and is effective in reducing scar in animal experiments. We report the case of a child with a distal esophageal stricture from lye ingestion managed with MMC. Despite repeated dilatations, at 1 year post injury, the stricture was 20% of esophageal diameter. Mitomycin C (4 microg/mL) was applied topically and circumferentially by endoscopy and repeated 4 months later. At 20 months follow-up, the child eats normally, and esophagram showed decreased stenosis (stricture was 50% of esophageal diameter). No complications were observed. Although controlled trials are required to confirm its efficacy, MMC should be considered as an adjunct in the management of caustic esophageal strictures in children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16677867     DOI: 10.1016/j.jpedsurg.2005.12.051

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  3 in total

1.  Minimally invasive management of children with caustic ingestion: less pain for patients.

Authors:  Unal Bicakci; Burak Tander; Gulay Deveci; Riza Rizalar; Ender Ariturk; Ferit Bernay
Journal:  Pediatr Surg Int       Date:  2010-03       Impact factor: 1.827

2.  Use of Mitomycin C for Refractory Esophageal Stricture following Tracheoesophageal Fistula Repair.

Authors:  Anna Lakoma; Sara C Fallon; Shawn Mathur; Eugene S Kim
Journal:  European J Pediatr Surg Rep       Date:  2013-03-19

3.  Primary nonendoscopic endonasal versus external dacryocystorhinostomy in nasolacrimal duct obstruction in children.

Authors:  Nandini Bothra; Raashid M Wani; Anasua Ganguly; Devjyoti Tripathy; Suryasnata Rath
Journal:  Indian J Ophthalmol       Date:  2017-10       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.